替奈普酶与阿替普酶桥接治疗患者的早期再通比较
该回顾性多中心注册研究比较替奈普酶与阿替普酶静脉溶栓后早期再通率,共纳入1865例前循环大血管闭塞急性缺血性卒中患者,总体早期再通率无显著差异(OR 1.09,95%CI 0.83-1.44,P=0.52);血栓长度>10 mm时替奈普酶早期再通几率更高(OR 2.43,95%CI 1.02-5.81,P=0.04),交互作用P=0.003。
要点
- 替奈普酶与阿替普酶早期再通率分别为19.8%和18.5%,无显著差异。
- 血栓长度>10 mm时替奈普酶早期再通几率高于阿替普酶(OR 2.43)。
- 静脉溶栓至再通评估时间及闭塞部位与早期再通无显著交互作用。
核心结论
- 两种溶栓药物在约五分之一的大血管闭塞急性缺血性卒中患者中实现早期再通,且与静脉溶栓至再通评估时间及闭塞部位无显著交互作用。
- 与阿替普酶相比,替奈普酶在较大血栓中与约2倍更高的早期再通几率相关。
研究设计与样本
- 回顾性比较来自PREDICT-RECANAL(阿替普酶)和Tenecteplase Treatment in Ischemic Stroke(替奈普酶)法国多中心注册的前循环大血管闭塞急性缺血性卒中患者。
- 共纳入1865例患者,采用倾向评分重叠加权分析,并以调整逻辑回归进行敏感性分析。
- 早期再通定义为首次血管造影或早期神经功能改善患者的无创血管影像上改良脑梗死溶栓评分2b-3分。
主要发现
- 替奈普酶组早期再通156/787(19.8%),阿替普酶组199/1078(18.5%),OR 1.09(95%CI 0.83-1.44),P=0.52。
- 血栓长度与治疗药物对早期再通概率存在交互作用(Pinteraction=0.003),血栓>10 mm时替奈普酶与更高早期再通几率相关(OR 2.43,95%CI 1.02-5.81,P=0.04)。
- 静脉溶栓至再通评估时间(Pinteraction=0.40)和闭塞部位(Pinteraction=0.80)与替奈普酶对比阿替普酶对早期再通的影响无交互作用。
关键数值与推荐
- 早期再通定义:首次血管造影或早期神经功能改善患者无创血管影像上改良脑梗死溶栓评分2b-3分。
- 血栓长度>10 mm亚组中替奈普酶对比阿替普酶的早期再通OR 2.43(95%CI 1.02-5.81),P=0.04。
- 总体早期再通OR 1.09(95%CI 0.83-1.44),P=0.52。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intravenous thrombolysis (IVT) with alteplase or tenecteplase before mechanical thrombectomy is the recommended treatment for large-vessel occlusion acute ischemic stroke. There are divergent data on whether these agents differ in terms of early recanalization (ER) rates before mechanical thrombectomy, and little data on their potential differences stratified by ER predictors such as IVT to ER evaluation (IVT-to-EReval) time, occlusion site and thrombus length. METHODS: We retrospectively compared the likelihood of ER after IVT with tenecteplase or alteplase in anterior circulation large-vessel occlusion acute ischemic stroke patients from the PREDICT-RECANAL (alteplase) and Tenecteplase Treatment in Ischemic Stroke (tenecteplase) French multicenter registries. ER was defined as a modified Thrombolysis in Cerebral Infarction score 2b-3 on the first angiographic run, or noninvasive vascular imaging in patients with early neurological improvement. Analyses were based on propensity score overlap weighting (leading to exact balance in patient history, stroke characteristics, and initial management between groups) and confirmed with adjusted logistic regression (sensitivity analysis). A stratified analysis based on pre-established ER predictors (IVT-to-EReval time, occlusion site, and thrombus length) was conducted. RESULTS: Overall, 1865 patients were included. ER occurred in 156/787 (19.8%) and 199/1078 (18.5%) patients treated with tenecteplase or alteplase, respectively (odds ratio, 1.09 [95% CI, 0.83-1.44]; P=0.52). A differential effect of tenecteplase versus alteplase on the probability of ER according to thrombus length was observed (Pinteraction=0.003), with tenecteplase being associated with higher odds of ER in thrombi >10 mm (odds ratio, 2.43 [95% CI, 1.02-5.81]; P=0.04). There was no differential effect of tenecteplase versus alteplase on the likelihood of ER according to the IVT-to-EReval time (Pinteraction=0.40) or occlusion site (Pinteraction=0.80). CONCLUSIONS: Both thrombolytics achieved ER in one-fifth of patients with large-vessel occlusion acute ischemic stroke without significant interaction with IVT-to-EReval time and occlusion site. Compared with alteplase, tenecteplase was associated with a 2-fold higher likelihood of ER in larger thrombi.
引用
- Checkouri T, Gerschenfeld G, Seners P, et al. Early Recanalization Among Patients Undergoing Bridging Therapy With Tenecteplase or Alteplase. Stroke. 2023. PMID: 37622385. doi:10.1161/STROKEAHA.123.042691
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。